International Union of Pharmacology. XXXV. The glucagon receptor family

Pharmacological Reviews

Volumn 55, Issue 1, 2003, Pages 167-194

  Mayo, Kelly E ^a   Miller, Laurence J ^b   Bataille, Dominique ^c   Dalle, Stéphane ^c   Göke, Burkhard ^d   Thorens, Bernard ^e   Drucker, Daniel J ^f,g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c INSERM   (France)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f UNIVERSITY OF TORONTO   (Canada)

^g TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCAGON RECEPTOR; SECRETIN;

BINDING AFFINITY; DRUG RECEPTOR BINDING; GENE STRUCTURE; GENETIC ORGANIZATION; HORMONE RELEASE; INTESTINE EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN PROCESSING; RECEPTOR GENE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURAL GENE; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; INTERNATIONAL AGENCIES; LIGANDS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 0037373183     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.55.1.6     Document Type: Review

References (412)

1. Abrahamsen N, Lundgren K, and Nishimura E (1995) Regulation of glucagon receptor mRNA in cultured primary rat hepatocytes by glucose and cAMP. J Biol Chem 270:15853-15857.
2. Abrahamsen N and Nishimura E (1995) Regulation of glucagon and glucagon-like peptide-1 receptor messenger ribonucleic acid expression in cultured rat pancreatic islets by glucose, cyclic adenosine 3′,5′-monophosphate and glucocorticoids. Endocrinology 136:1572-1578
3. Abribat T, Boulanger L, and Gaudreau P (1990) Characterization of [125ITyr10]human growth hormone-releasing factor (1-44) amide binding to rat pituitary: evidence for high and low affinity classes of sites. Brain Res 528:291-299.
4. Agerso H, Jensen LB, Elbrond B, Rolan P, and Zdravkovic M (2002) The pharmacokinetics, pharmacodymamics, safety and tolerability of NN2211, a new longacting GLP-1 derivative, in healthy men. Diabetologia 45:195-202.
5. Alavi K, Schwartz MZ, Palazzo JP, and Prasad R (2000) Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 35:847-851.
6. Aleppo G, Moskal SF 2nd, De Grandis PA, Kineman RD, and Frohman, LA (1997) Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology 138:1058-1065.
7. Almind K, Ambye L, Urhammer SA, Hansen T, Echwald SM, Holst JJ, Gromada J, Thorens B, and Pedersen O (1998) Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 41:1194-1198.
8. Asmann YW, Dong M, Ganguli S, Hadac EM, and Miller LJ (2000) Structural insights into the amino terminus of the secretin receptor: I. Status of cysteine and cystine residues. Mol Pharmacol 58:911-919.
9. Baetens D, Rufener C, Srikant BC, Dobbs R, Unger R, and Orci L (1976) Identification of glucagon-producing cells (A cells) in dog gastric mucosa. J Cell Biol 69:455-464.
10. Bagnato A, Moretti C, Ohnishi J, Frajese G, and Catt KJ (1992) Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary. Endocrinology 130:1097-1102.
11. Barinaga M, Yamonoto G, Rivier C, Vale W, Evans R, and Rosenfeld MG (1983) Transcriptional regulation of growth hormone gene expression by growth hormone-releasing factor. Nature (Lond) 306:84-85.
12. Barragan JM, Eng J, Rodriguez R, and Blazquez E (1999) Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 277:E784-E791.
13. Bataille D (1996a) Oxyntomodulin and its related peptides, in Glucagon III (Lefebvre PJ ed) pp 327-340, Springer-Verlag, Berlin.
14. Bataille D (1996b) Preproglucagon and its processing, in Glucagon III (Lefebvre PJ ed) pp 31-51, Springer-Verlag, Berlin.
15. Baum J, Simon BF, Unger RH, and Madison LL (1962) Localization of glucagon in the alpha cells in the pancreatic islet by immunofluoreseent techniques. Diabetes 11:371-374.
16. Baumann G and Maheshwari H (1997) The Dwarfs of Sindh: severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. Acta Paediatr Suppl 423:33-38.
17. Bayliss WM and Starling EH (1902) On the causation of the so-called "peripheral reflex secretion" of the pancreas. Proc R Soc Lond Biol 69:352-353.
18. Beak SA, Small CJ, Ilovaiskaia I, Hurley JD, Ghatei MA, Bloom SR, and Smith DM (1996) Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. Endocrinology 137:4130-4138.
19. Bell GI, Sanchez-Pescador R, Laybourn PJ, and Najarian RC (1983a) Exon duplication and divergence in the human preproglucagon gene. Nature (Lond) 304:368-371.
20. Bell GI, Santerre RF, and Mullenbach GT (1983b) Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature (Lond) 302:716-718.
21. Benjamin MA, McKay DM, Yang PC, Cameron H, and Perdue MH (2000) Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47:112-119.
22. Berry SA and Pescovitz OH (1988) Identification of a rat GHRH-like substance and its messenger RNA in rat testis. Endocrinology 123:661-663.
23. Billestrup N, Swanson LW, and Vale W (1986) Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci USA 83:6854-6857.
24. Bjerknes M and Cheng H (2001) Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 98:12497-12502.
25. Bode HP, Moormann B, Dabew R, and Goke B (1999) Glucagon-like peptide 1 elevates cytosolic calcium in pancreatic beta-cells independently of protein kinase A. Endocrinology 140:3919-3927.
26. Boisvert C, Pare C, Veyrat-Durebex C, Robert A, Dubuisson S, Morel G, and Gaudreau P (2002) Localization and regulation of a functional GHRH receptor in the rat renal medulla. Endocrinology 143:1475-1484.
27. Bollag RJ, Zhong Q, Phillips P, Min L, Zhong L, Cameron R, Mulloy AL, Rasmussen H, Qin F, Ding KH, et al. (2000) Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 141:1228-1235.
28. Boushey RP, Yusta B, and Drucker DJ (1999) Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 277:E937-E947.
29. Boushey RP, Yusta B, and Drucker DJ (2001) Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 61:687-693.
30. Boylan MO, Jepeal LI, and Wolfe MM (1999) Structure of the rat glucose-dependent insulinotropic polypeptide receptor gene. Peptides 20:219-228.
31. Breyer PR, Rothrock JK, Beaudry N, and Pescovitz OH (1996) A novel peptide from the growth hormone releasing hormone gene stimulates Sertoli cell activity. Endocrinology 137:2159-2162.
32. Bromer WW, Sinn LG, Staub A, and Behrens OK (1956) The amino acid sequence of glucagon. J Am Chem Soc 78:3858-3859.
33. Brown JC (1982) Gastric inhibitory polypeptide, in Monographs in Endocrinology, Springer-Verlag, Heidelberg.
34. Brubaker PL, Izzo A, Hill M, and Drucker DJ (1997) Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 272:E1050-E1058.
35. Buggy JJ, Heurich RO, MacDougall M, Kelley KA, Livingston JN, Yoo-Warren H, and Rossomando AJ (1997) Role of the glucagon receptor COOH-terminal domain in glucagon-mediated signaling and receptor internalization. Diabetes 46:1400-1405.
36. Buhl T, Thim L, Kofod H, Orskov C, Harling H, and Holst JJ (1988) Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine. J Biol Chem 263:8621-8624.
37. Bullock BP, Heller RS, and Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor. Endocrinology 137:2968-2978.
38. Burcelin R, Dolci W, and Thorens B (1999a) Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 48:252-258.
39. Burcelin R, Li J, and Charron MJ (1995) Cloning and sequence analysis of the murine glucagon receptor-encoding gene. Gene (Amst) 164:305-310.
40. Burcelin R, Rolland E, Dolci W, Germain S, Carrel V, and Thorens B (1999b) Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Ann NY Acad Sci 875:277-285.
41. Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P, and Szepeshazi K (2002) The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA 99:11866-11871.
42. Butlen D and Morel F (1985) Glucagon receptors along the nephron: [125I]glucagon binding in rat tubules. Pfluegers Arch 404:348-353.
43. Byrne MM and Goke B (1996) Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use. Diabet Med 13:854-860.
44. Campbell RM, Lee Y, Rivier J, Heimer EP, Felix AM, and Mowles TF (1991) GRF analogs and fragments: correlation between receptor binding, activity and structure. Peptides 12:569-574.
45. Campbell RM and Scanes CG (1992) Evolution of the growth hormone-releasing factor (GRF) family of peptides. Growth Regul 2:175-191.
46. Canonico PL, Cronin MJ, Thorner MO, and MacLeod RM (1983) Human pancreatic GRF stimulates phosphatidylinositol labeling in cultured anterior pituitary cells. Am J Physiol 245:E587-E590.
47. Carruthers CJL, Unson CG, Kim HN, and Sakmar TP (1994) Synthesis and expression of a gene for the rat glucagon receptor. Replacement of an aspartic acid in the extracellular domain prevents glucagon binding. J Biol Chem 269:29321-29328.
48. Cervini LA, Donaldson CJ, Koerber SC, Vale WW, and Rivier JE (1998) Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. J Med Chem 41:717-727.
49. Chance WT, Foley-Nelson T, Thomas I, and Balasubramaniam A (1997) Prevention of parenteral nutrition-induced gut hyoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol 273:G559-G563.
50. Chance WT, Sheriff S, Foley-Nelson T, Thomas I, and Balasubramaniam A (2000) Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: effects of glucagon-like peptide 2. Nutr Cancer 37:215-222.
51. Cheeseman CI and Tsang R (1996) The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport. Am J Physiol 271:G477-G482.
52. Chen C, Vincent JD, and Clarke IJ (1994) Ion channels and the signal transduction pathways in the regulation of growth hormone secretion. Trends Endocrinol Metab 5:227-233.
53. Chepurny OG and Holz GG (2002) Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation. Cell Tissue Res 307:191-201.
54. Chiba T, Yamatani T, Yamaguchi A, Morishita T, Nakamura A, Kadowaki S, and Fujita T (1989) Mechanism for increase of gastrin release by secretin in ZollingerEllison syndrome. Gastroenterology 96:1439-1444.
55. Chicchi GG, Cascieri MA, Graziano MP, Calahan T, and Tota MR (1997) FluoresceinTrp25-exendin-4, a biologically active fluorescent probe for the human GLP-1 receptor. Peptides 18:319-321.
56. Chow BK (1995) Molecular cloning and functional characterization of a human secretin receptor. Biochem Biophys Res Commun 212:204-211.
57. Christophe J (1996) Glucagon and its receptor in various tissues. Ann NY Acad Sci 805:31-42; discussion 805:42-43.
58. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, and Sexton PM (2002) Novel receptor partners and function of receptor activity modifying proteins. J Biol Chem epub ahead of print.
59. Ciampani T, Fabbri A, Isidori A, and Dufau ML (1992) Growth hormone-releasing hormone is produced by rat Leydig cell in culture and acts as a positive regulator of Leydig cell function. Endocrinology 131:2785-2792.
60. Claus TH, Park CR, and Pilkis SJ (1983) Glucagon and gluconeogenesis, in Glucagon I (Lefebvre PJ ed) pp 315-360, Springer-Verlag, Berlin.
61. Coniglio SJ, Lewis JD, Lang C, Burns TG, Subhani-Siddique R, Weintraub A, Schub H, and Holden EW (2001) A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr 138:649-655.
62. Coy DH, Jiang NY, Fuselier J, and Murphy WA (1996) Structural simplification of potent growth hormone-releasing hormone analogs: implications for other members of the VIP/GHRH/PACAP family. Ann NY Acad Sci 805:149-158.
63. Cypess AM, Unson CG, Wu CR, and Sakmar TP (1999) Two cytoplasmic loops of the glucagon receptor are required to elevate cAMP or intracellular calcium. J Biol Chem 274:19455-19464.
64. DaCambra MP, Yusta B, Sumner-Smith M, Crivici A, Drucker DJ, and Brubaker PL (2000) Structural determinants for activity of glucagon-like peptide-2. Biochemistry 39:8888-8894.
65. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, and Bloom SR (2001) Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:4244-4250.
66. Dalle S, Fontes G, Lajoix AD, LeBrigand L, Gross R, Ribes G, Dufour M, Barry L, LeNguyen D, and Bataille D (2002) Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes 51:406-412.
67. Dalle S, Smith P, Blache P, Le-Nguyen D, Le Brigand L, Bergeron F, Ashcroft FM, and Bataille D (1999) Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem 274:10869-10876.
68. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, and Holst, JJ (1998) Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41:271-278.
69. DeAlmeida VI and Mayo KE (1998) Identification of binding domains of the growth hormone-releasing hormone receptor by analysis of mutant and chimeric receptor proteins. Mol Endocrinol 12:750-765.
70. de Herder WW, Hofland LJ, Usdin TB, de Jong FH, Uitterlinden P, van Koetsveld P, Mezey E, Bonner TI, Bonjer HJ, and Lamberts SW (1996) Food-dependent Cushing's Syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin Endocrinol Metab 81:3168-3172.
71. De Meester I, Korom S, Van Damme J, and Scharpe S (1999) CD26, let it cut or cut it down. Immunol Today 20:367-375.
72. Diamant B and Picazo J (1983) Spasmolytic and clinical use of glucagon, in Glucagon II (Lefebvre PJ ed) pp 611-643, Springer-Verlag, Berlin.
73. Dillon JS, Tanizawa Y, Wheeler MB, Leng X-H, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, and Boyd AE III (1993) Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology 133:1907-1910.
74. Ding WQ, Cheng ZJ, McElhiney J, Kuntz SM, and Miller LJ (2002a) Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Res 62:5223-5229.
75. Ding WQ, Kuntz S, Bohmig M, Wiedenmann B, and Miller LJ (2002b) Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. Gastroenterology 122:500-511.
76. Dong M, Wang Y, Hadac EM, Pinon DI, Holicky E, and Miller LJ (1999a) Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor. J Biol Chem 274:19161-19167.
77. Dong M, Wang Y, and Miller LJ (2000) Dual contacts between peptide agonist ligands and the secretin receptor directly established by photoaffinity labeling. Ann NY Acad Sci 921:381-386.
78. Dong M, Wang Y, Pinon DI, Hadac EM, and Miller LJ (1999b) Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the amino-terminal tail of the secretin receptor using photoaffinity labeling. J Biol Chem 274:903-909.
79. Dong M, Zang M, Pinon DI, Li Z, Lybrand TP, and Miller LJ (2002) Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus. Mol Endocrinol 16:2490-2501.
80. Doyle ME, Greig NH, Holloway HW, Betkey JA, Bernier M, and Egan JM (2001) Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent. Endocrinology 142:4462-4468.
81. Drucker DJ (1998) The glucagon-like peptides. Diabetes 47:159-169.
82. Drucker DJ (2001a) Develepment of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharm Des 7:1399-1412.
83. Drucker DJ (2001b) Glucagon-like peptide 2. J Clin Endocrinol Metab 86:1759-1764.
84. Drucker DJ (2001c) Minireview: the glucagon-like peptides. Endocrinology 142:521-527.
85. Drucker DJ (2002) Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531-544.
86. Drucker DJ (2003) Glucagon-like peptides: regulators of cell proliferation, differentiation and apoptosis. Mol Endocrinol 17:161-171.
87. Drucker DJ and Asa S (1988) Glucagon gene expression in vertebrate brain. J Biol Chem 263:13475-13478.
88. Drucker DJ, Boushey RP, Wang F, Hill ME, Brubaker PL, and Yusta B (1999a) Biologic properties and therapeutic potential of glucagon-like peptide-2. J Parenter Enteral Nutr 23 (Suppl 5):S98-S100.
89. Drucker DJ, DeForest L, and Brubaker PL (1997a) Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am J Physiol 273:G1252-G1262.
90. Drucker DJ, Ehrlich P, Asa SL, and Brubaker PL (1996) Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93:7911-7916.
91. Drucker DJ, Philippe J, Mojsov S, Chick WL, and Habener JF (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438.
92. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, and Brubaker PL (1997b) Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15:673-677.
93. Drucker DJ, Yusta B, Boushey RP, Deforest L, and Brubaker PL (1999b) Human [Gly2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 276:G79-G91.
94. Dunphy JL, Taylor RG, and Fuller PJ (1998) Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 141:179-186.
95. Dupre J and Beck JC (1966) Stimulation of release of insulin by an extract of intestinal mucosa. Diabetes 15:555-559.
96. Dupre J, Ross SA, Watson D, and Brown JC (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826-828.
97. Eaton RP (1977) Glucagon and lipoprotein regulation in man, in Glucagon: Its Role in Physiology and Clinical Medicine (Foa PP, Bajaj JS, and Foa NL eds) p 553, Springer-Verlag, Berlin.
98. Ebert R and Creutzfeldt W (1987) Gastrointestinal peptides and insulin secretion. Diabetes Metab Rev 3:1-26.
99. Egan JM, Clocquet AR, and Elahi D (2002) The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87:1282-1290.
100. Ehses JA, Lee SS, Pederson RA, and McIntosh CH (2001) A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: evidence for the involvement of phospholipase A2 in GIP-stimulated insulin secretion. J Biol Chem 276:23667-23673.
101. Ehses JA, Pelech SL, Pederson RA, and McIntosh CH (2002) Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277:37088-37097.
102. Eicher EM and Beamer WG (1976) Inherited ateliotic dwarfism in mice. Characteristics of the mutation, little, on chromosome 6. J Hered 67:87-91.
103. Escobar DC, Vicentini LM, Ghigo E, Ciccarelli E, Usellini L, Capella C, and Cocchi D (1986) Growth hormone-releasing factor does not stimulate phosphoinositides breakdown in primary cultures of rat and human pituitary cells. Acta Endocrinol (Copenh) 112:345-350.
104. Farah AE (1983) Glucagon and the heart, in Glucagon II (Lefebvre PJ ed) pp 553-609, Springer-Verlag, Berlin.
105. Fehmann H-C and Goke B (1995) Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription. Peptides 16:1149-1152.
106. Fehmann H-C, Goke R, and Goke B (1995a) Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent releasing polypeptide. Endocr Rev 16:390-410.
107. Fehmann HC and Habener JF (1991) Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line. FEBS Lett 279:335-340.
108. Fehmann H-C and Habener JF (1992) Insulinotropic hormone glucagon-like peptideI(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinology 130:159-166.
109. Fehmann HC, Hering BJ, Wolf MJ, Brandhorst H, Brandhorst D, Bretzel RG, Federlin K, and Goke B (1995b) The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas 11:196-200.
110. French MB, Lussier BT, Moor BC, and Kraicer J (1990) Effect of growth hormone-releasing factor on phosphoinositide hydrolysis in somatotrophs. Mol Cell Endocrinol 72:221-226.
111. Frohman LA, Downs TR, Heimer EP, and Felix AM (1989a) Dipeptidyl peptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Investig 83:1533-1540.
112. Frohman LA and Jansson JO (1986) Growth hormone-releasing hormone. Endocr Rev 7:223-253.
113. Frohman LA and Szabo M (1981) Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly. Prog Clin Biol Res 74:259-271.
114. Frohman MA, Downs TR, Chomczynski P, and Frohman LA (1989b) Cloning and characterization of mouse growth hormone-releasing hormone (GRH) complementary DNA: increased GRH messenger RNA levels in the growth hormone-deficient lit/lit mouse. Mol Endocrinol 3:1529-1536.
115. Galehshahi FS, Goke B, and Lankat-Buttgereit B (1998) Contribution of a PSI-like element to the tissue- and cell-specific expression of the human GLP-1 receptor gene. FEBS Lett 436:163-168.
116. Gardner JD, Conlon TP, Fink ML, and Bodanszky M (1976) Interaction of peptides related to secretin with hormone receptors on pancreatic acinar cells. Gastroenterology 71:965-970.
117. Gault VA, O'Harte FP, Harriott P, and Flatt PR (2002) Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 290:1420-1426.
118. Gaylinn BD (1999) Molecular and cell biology of the growth hormone-releasing hormone receptor. Growth Horm IGF Res 9 (Suppl A):37-44.
119. Gaylinn BD, Dealmeida VI, Lyons CE Jr, Wu KC, Mayo KE, and Thorner MO (1999) The mutant growth hormone-releasing hormone (GHRH) receptor of the little mouse does not bind GHRH. Endocrinology 140:5066-5074.
120. Gaylinn BD, Harrison JK, Zysk JR, Lyons CE, Lynch KR, and Thorner MO (1993) Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. Mol Endocrinol 7:77-84.
121. Gaylinn BD, Lyons CE, Zysk JR, Clarke IJ, and Thorner MO (1994a) Photoaffinity cross-linking to the pituitary receptor for growth hormone-releasing factor. Endocrinology 135:950-955.
122. Gaylinn BD, von Kap-Herr C, Golden WL, and Thorner MO (1994b) Assignment of the human growth hormone-releasing hormone receptor gene (GHRHR) to 7p14 by in situ hybridization. Genomics 19:193-195.
123. Gelling RW, Coy DH, Pederson RA, Wheeler MB, Hinke S, Kwan T, and McIntosh CH (1997a) GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro. Regul Pept 69:151-154.
124. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100:1438-1443.
125. Gelling RW, Wheeler MB, Xue J, Gyomorey S, Nian C, Pederson RA, and McIntosh CH (1997b) Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor. Endocrinology 138:2640-2643.
126. Gick GG, Zeytin FN, Brazeau P, Ling NC, Esch FS, and Bancroft C (1984) Growth hormone-releasing factor regulates growth hormone mRNA in primary cultures of rat pituitary cells. Proc Natl Acad Sci USA 81:1553-1555.
127. Girard N, Boulanger L, Denis S, and Gaudreau P (1999) Differential in vivo regulation of the pituitary growth hormone-releasing hormone (GHRH) receptor by GHRH in young and aged rats. Endocrinology 140:2836-2842.
128. Godfrey P, Rahal JO, Beamer WG, Copeland NG, Jenkins NA, and Mayo KE (1993) GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat Genet 4:227-232.
129. Goke R, Cole T, and Conlon JM (1989a) Characterization of the receptor for glucagon-like peptide-1(7-36)amide on plasma membranes from rat insulinoma-derived cells by covalent cross-linking. J Mol Endocrinol 2:93-98.
130. Goke R and Conlon JM (1988) Receptors for glucagon-like peptide-1(7-36) amide on rat insulinoma-derived cells. J Endocrinol 116:357-362.
131. Goke R, Fehmann H-C, Linn T, Schmidt H, Krause M, Eng J, and Goke B (1993) Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268:19650-19655.
132. Goke R, Just R, Lankat-Buttgereit B, and Goke B (1994) Glycosylation of the GLP-1 receptor is a prerequisite for regular receptor function. Peptides 15:675-681.
133. Goke R, Larsen PJ, Mikkelsen JD, and Sheikh SP (1995) Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7:2294-2300.
134. Goke R, Oltmer B, Sheikh SP, and Goke B (1992) Solubilization of active GLP-1(736)amide receptors from RINm5F plasma membranes. FEBS Lett 300:232-236.
135. Goke R, Trautmann ME, Haus E, Richter G, Fehmann HC, Arnold R, and Goke B (1989b) Signal transmission after GLP-1(7-36)amide binding in RINm5F cells. Am J Physiol 257:G397-G401.
136. Graziano MP, Hey PJ, Borkowski D, Chicchi GG, and Strader CD (1993) Cloning and functional expression of a human glucagon-like peptide-1 receptor. Biochem. Biophys Res Commun 196:141-146.
137. Gremlich S, Porret A, Hani EH, Cherif D, Vionnet D, Froguel P, and Thorens B (1995) Cloning, functional expression and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44:1202-1208.
138. Gros L, Demiprence E, Bataille D, and Kervra A (1992) Characterization of high affinity receptors for glucagon-like peptide-1 (7-36)amide on a somatostatin-secreting cell line. Biomed Res 13:143-150.
139. Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, and Wehrenberg WB (1982) Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science (Wash DC) 218:585-587.
140. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, and Beglinger C (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541-R1544.
141. Haffar BM, Hocart SJ, Coy DH, Mantey S, Chiang HC, and Jensen RT (1991) Reduced peptide bond pseudopeptide analogues of secretin. A new class of secretin receptor antagonists. J Biol Chem 266:316-322.
142. Hager J, Hansen L, Vaisse C, Vionnet N, Philippi A, Poller W, Velho G, Carcassi C, Contu L, and Julier C (1995) A missense mutation in the glucagon receptor gene is associated with non-insulin-dependent diabetes mellitus. Nat Genet 9:299-304.
143. Hallbrink M, Holmqvist T, Olsson M, Ostenson CG, Efendic S, and Langel U (2001) Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation. Biochim Biophys Acta 1546:79-86.
144. Halmos G, Schally AV, Czompoly T, Krupa M, Varga JL, and Rekasi Z (2002) Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer. J Clin Endocrinol Metab 87:4707-4714.
145. Hammer RE, Brinster RL, Rosenfeld MG, Evans RM, and Mayo KE (1985) Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth. Nature (Lond) 315:413-416.
146. Hansen AB, Gespach CP, Rosselin GE, and Holst JJ (1988) Effect of truncated glucagon-like peptide 1 on cAMP in rat gastric glands and HGT-1 human gastric cancer cells. FEBS Lett 236:119-122.
147. Hansen BS, Gerlach LO, Hansen A, Foged C, and Andersen PH (2001) The growth hormone-releasing hormone receptor: desensitisation following short-term agonist exposure. Pharmacol Toxicol 88:81-88.
148. Hansen LH, Gromada J, Bouchelouche P, Whitmore T, Jelinek L, Kindsvogel W, and Nishimura E (1998) Glucagon-mediated Ca2+ signaling in BHK cells expressing cloned human glucagon receptors. Am J Physiol 274 (6 Pt 1):C1552-C1562.
149. Harmar AJ (2001) Family-B G-protein-coupled receptors. Genome Biol 2:REVIEWS3013.
150. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, and Holst JJ (2000a) In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85:2884-2888.
151. Hartmann B, Thulesen J, Hare KJ, Kissow H, Orskov C, Poulsen SS, and Holst JJ (2002) Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul Pept 105:173-179.
152. Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Paulsen SS, and Holst JJ (2000b) Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 141:4013-4020.
153. Hashimoto K, Koga M, Motomura T, Kasayama S, Kouhara H, Ohnishi T, Arita N, Hayakawa T, Sato B, and Kishimoto T (1995) Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas. J Clin Endocrinol Metab 80:2933-2939.
154. Hassan HA (2001) Biological activities of two porcine growth hormone-releasing hormone receptor isoforms. Arch Biochem Biophys 387:20-26.
155. Hassan HA, Hsiung HM, Zhang XY, Smith DP, Smiley DL, and Heiman ML (1995) Characterization of growth hormone-releasing hormone (GHRH) binding to cloned porcine GHRH receptor. Peptides 16:1469-1473.
156. Heller RS, Kieffer TJ, and Habener JF (1997) Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46:785-791.
157. Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth HU, and McIntosh CH (2002) Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51:652-661.
158. Hinke SA, Manhart S, Pamir N, Demuth H, Gelling RW, Pederson RA and McIntosh, CH (2001) Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochim Biophys Acta 1547:143-155.
159. Ho PK, Fong RS, Kai HS, Lau EH, Ngan ES, Cotton CU, and Chow BK (1999) The human secretin receptor gene: genomic organization and promoter characterization. FEBS Lett 455:209-214.
160. Holl RW, Thorner MO, and Leong DA (1988) Intracellular calcium concentration and growth hormone secretion in individual somatotropes: effects of growth hormone-releasing factor and somatostatin. Endocrinology 122:2927-2932.
161. Holst JJ, Gromada J, and Nauck MA (1997) The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40:984-986.
162. Holtmann MH, Ganguli S, Hadac EM, Dolu V, and Miller LJ (1996a) Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. J Biol Chem 271:14944-14949.
163. Holtmann MH, Hadac EM, and Miller LJ (1995) Critical contributions of aminoterminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors. J Biol Chem 270:14394-14398.
164. Holtmann MR, Roettger BF, Pinon DI, and Miller LJ (1996b) Role of receptor phosphorylation in desensitization and internalization of the secretin receptor. J Biol Chem 271:23566-23571.
165. Holz GG, Leech CA, and Habener JF (1995) Activation of a cAMP-regulated Ca2+signaling pathway in pancreatic b-cells by the insulinotropic hormone glucagonlike peptide-1. J Biol Chem 270:17749-17757.
166. Holz GG, Leech CA, Heller RS, Castonguay M, and Habener JF (1999) cAMPdependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J Biol Chem 274:14147-14156.
167. Hoosein NM and Gurd RS (1984a) Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase. FEBS Lett 178:83-86.
168. Hoosein NM and Gurd RS (1984b) Identification of glucagon receptors in rat brain. Proc Natl Acad Sci USA 81:4368-4372.
169. Horikawa R (2002) [Isolated GH deficiency due to inactivating mutation of GHRH receptor]. Nippon Rinsho 60:297-305.
170. Horikawa R, Gaylinn BD, Lyons CE Jr, and Thorner MO (2001) Molecular cloning of ovine and bovine growth hormone-releasing hormone receptors: the ovine receptor is C-terminally truncated. Endocrinology 142:2660-2668.
171. Horikawa R, Hellmann P, Cella SG, Torsello A, Day RN, Muller EE, and Thorner MO (1996) Growth hormone-releasing factor (GRF) regulates expression of its own receptor. Endocrinology 137:2642-2645.
172. Hsiung HM, Smith DP, Zhang XY, Bennett T, Rosteck PR Jr, and Lai MH (1993) Structure and functional expression of a complementary DNA for porcine growth hormone-releasing hormone receptor. Neuropeptides 25:1-10.
173. Huypens P, Ling Z, Pipeleers D, and Schuit F (2000) Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 43:1012-1019.
174. Iguchi G, Okimura Y, Takahashi T, Mizuno I, Fumoto M, Takahashi Y, Kaji H, Abe H, and Chihara K (1999) Cloning and characterization of the 5′-flanking region of the human growth hormone-releasing hormone receptor gene. J Biol Chem 274:12108-12114.
175. Irwin DM (2001) Molecular evolution of proglucagon. Regul Pept 98:1-12.
176. Isenberg JI, Walsh JH, Passaro E Jr, Moore EW, and Grossman MI (1972) Unusual effect of secretin on serum gastrin, serum calcium and gastric acid secretion in a patient with suspected Zollinger-Ellison syndrome. Gastroenterology 62:626-631.
177. Ishihara T, Nakamura S, Kaziro Y, Takahashi T, Takahashi K, and Nagata S (1991) Molecular cloning and expression of a cDNA encoding the secretin receptor. EMBO (Eur Mol Biol Organ) J 10:1635-1641.
178. Iyengar R and Herberg JT (1984) Structural analysis of the hepatic glucagon receptor. Identification of a guanine nucleotide-sensitive hormone-binding region. J Biol Chem 259:5222-5229.
179. Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, Bensch PA, Kuijper JL, Sheppard PO, Sprecher CA, et al. (1993) Expression cloning and signaling properties of the rat glucagon receptor. Science (Wash DC) 259:1614-1616.
180. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, et al. (2001) Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120:806-815.
181. Jin S-LC, Han VKM, Simmons JG, Towle AC, Lauder JM, and Lund PK (1988) Distribution of glucagonlike peptide 1 (GLP-1), glucagon and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271:519-532.
182. Josefsson LG (1999) Evidence for kinship between diverse G-protein coupled receptors. Gene (Amst) 239:333-340.
183. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, and Schmitz O (2002) Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51:424-429.
184. Kajkowski EM, Price LA, Pausch MH, Young KH, and Ozenberger BA (1997) Investigation of growth hormone releasing hormone receptor structure and activity using yeast expression technologies. J Recept Signal Transduct Res 17:293-303.
185. Kang G, Chepurny OG, and Holz GG (2001) cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca(2+)-induced Ca(2+) release in INS-1 pancreatic beta-cells. J Physiol (Lond) 536:375-385.
186. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, and Seino S (2001) Critical role of cAMP-GEFII/Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276:45045-45053.
187. Kastin AJ, Akerstrom V, and Pan W (2002) Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18:7-14.
188. Kato Y, Yu D, and Schwartz MZ (1999) Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg 34:18-20.
189. Kawai K, Yokota C, Ohashi S, Watanabe Y, and Yamashita K (1995) Evidence that glucagon stimulates insulin secretion through its own receptor in rats. Diabetologia 38:274-276.
190. Kenny AJ (1955) Extractable glucagon of the human pancreas. J Clin Endocrinol Metab 15:1089-1105.
191. Kieffer TJ and Habener JF (1999) The glucagon-like peptides. Endocr Rev 20:876-913.
192. Kieffer TJ, McIntosh CH, and Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596.
193. Kimball CP and Murlin JR (1923) Aqueous extracts of pancreas. J Biol Chem 58:337-346.
194. Kineman RD (2000) Antitumorigenic actions of growth hormone-releasing hormone antagonists. Proc Natl Acad Sci USA 97:532-534.
195. Kolligs F, Fehmann H-C, Goke R, and Goke B (1995) Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44:16-19.
196. Kopin AS, Wheeler MB, and Leiter AB (1990) Secretin: structure of the precursor and tissue distribution of the mRNA. Proc Natl Acad Sci USA 87:2299-2303.
197. Kopin AS, Wheeler MB, Nishitani J, McBride EW, Chang TM, Chey WY, and Leiter AB (1991) The secretin gene: evolutionary history, alternative splicing and developmental regulation. Proc Natl Acad Sci USA 88:5335-5339.
198. Korytko AI and Cuttler L (1997) Thyroid hormone and glucocorticoid regulation of pituitary growth hormone-releasing hormone receptor gene expression. J Endocrinol 152:R13-R37.
199. Korytko AI, Zeitler P, and Cuttler L (1996) Developmental regulation of pituitary growth hormone-releasing hormone receptor gene expression in the rat. Endocrinology 137:1326-1331.
200. Kubiak TM, Friedman AR, and Moseley WM (1996) Synthetic analogs of growth hormone releasing factor (GHRF) with improved pharmaceutical properties, in Growth Hormone Secretagogues (Berc BB and Walker RF eds) pp 31-52, Springer Publishing, New York.
201. Kubota A, Yamada Y, Hayami T, Yasuda K, Someya Y, Ihara Y, Kagimoto S, Watanabe R, Taminato T, Tsuda K, et al. (1996) Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 45:1701-1705.
202. Kubota A, Yamada Y, Yasuda K, Someya Y, Ihara Y, Kagimoto S, Watanabe R, Kuroe A, Ishida H, and Seino Y (1997) Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and -insensitive pathways. Biochem Biophys Res Commun 235:171-175.
203. Ladouceur GH, Cook JH, Doherty EM, Schoen WR, MacDougall ML, and Livingston JN (2002) Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists. Bioorg Med Chem Lett 12:461-464.
204. Lam KS, Lee MF, Tam SP, and Srivastava G (1996) Gene expression of the receptor for growth-hormone-releasing hormone is physiologically regulated by glucocorticoids and estrogen. Neuroendocrinology 63:475-480.
205. Lance VA, Murphy WA, Sueiras-Diaz J, and Coy DH (1984) Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochem Biophys Res Commun 119:265-272.
206. Lankat-Buttgereit B and Goke B (1997) Cloning and characterization of the 5′flanking sequences (promoter region) of the human GLP-1 receptor gene. Peptides 18:617-624.
207. Lankat-Buttgereit B, Goke R, Fehmann H-C, Richter G, and Goke B (1994) Molecular cloning of a cDNA encoding for the GLP-1 receptor expressed in rat lung. Exp Clin Endocrinol 102:341-347.
208. Larsen PJ, Tang-Christensen M, Holst JJ, and Orskov C (1997) Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77:257-270.
209. Lasko CM, Korytko AI, Wehrenberg WB, and Cuttler L (2001) Differential GHreleasing hormone regulation of GHRH receptor mRNA expression in the rat pituitary. Am J Physiol Endocrinol Metab 280:E626-E631.
210. Lee EJ, Kotlar TJ, Ciric I, Lee MK, Lim SK, Lee HC, Huh KB, Mayo KE, and Jameson JL (2001) Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors. J Clin Endocrinol Metab 86:3989-3995.
211. Leiter AB, Chey WY, and Kopin AS (1994) Secretin, in Gut Peptides: Biochemistry and Physiology (Walsh JH and Dockray GJ eds) pp 147-174, Raven Press, New York.
212. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, and Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478.
213. Light PE, Manning Fox JE, Riedel MJ, and Wheeler MB (2002) Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol Endocrinol 16:2135-2144.
214. Lin C, Lin SC, Chang CP, and Rosenfeld MG (1992) Pit-1-dependent expression of the receptor for growth hormone releasing factor mediates pituitary cell growth. Nature (Lond) 360:765-768.
215. Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, and Rosenfeld MG (1993) Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature (Lond) 364:208-213.
216. Ling A, Hong Y, Gonzalez J, Gregor V, Polinsky A, Kuki A, Shi S, Teston K, Murphy D, Porter J, et al. (2001a) Identification of alkylidene hydrazides as glucagon receptor antagonists. J Med Chem 44:3141-3149.
217. Ling A, Plewe M, Gonzalez J, Madsen P, Sams CK, Lau J, Gregor V, Murphy D, Teston K, Kuki A, et al. (2002) Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem Lett 12:663-666.
218. Ling N, Baird A, Wehrenberg WB, Ueno N, Munegumi T, and Brazeau P (1984a) Synthesis and in vitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor. Biochem Biophys Res Commun 123:854-861.
219. Ling N, Esch F, Bohlen P, Brazeau P, Wehrenberg WB, and Guillemin R (1984b) Isolation, primary structure and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. Proc Natl Acad Sci USA 81:4302-4306.
220. Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG, and Schuit FC (2001b) Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438:382-387.
221. Lok S, Kuijper JL, Jelinek LJ, Kramer JM, Whitmore TE, Sprecher CA, Mathewes S, Grant FJ, Biggs SH, and Rosenberg GB (1994) The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. Gene (Amst) 140:203-209.
222. Lopez LC, Frazier ML, Su CJ, Kumar A, and Saunders GF (1983) Mammalian pancreatic preproglucagon contains three glucagon-related peptides. Proc Natl Acad Sci USA 80:5485-5489.
223. Lotersztajn S, Pavoine C, Brechler V, Roche B, Dufour M, Le-Nguyen D, Bataille D, and Pecker F (1990) Glucagon-(19-29) exerts a biphasic action on the liver plasma membrane Ca2+ pump which is mediated by G proteins. J Biol Chem 265:9876-9880.
224. Lovshin J, Estall J, Yusta B, Brown TJ, and Drucker DJ (2001) Glucagon-like peptide-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 276:21489-21499.
225. Lovshin J, Yusta B, Iliopoulos I, Migirdicyan A, Dableh L, Brubaker PL, and Drucker DJ (2000) Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. Endocrinology 141:4194-4201.
226. Lu M, Wheeler MB, Leng X-H, and Boyd AEI (1993) The role of the free cytoplasmic calcium level in β-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). Endocrinology 132:94-100.
227. Lund PK, Goodman RH, Dee PC, and Habener JF (1982) Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci USA 79:345-349.
228. Lussier BT, French MB, Moore BC, and Kraicer J (1991) Free intracellular Ca2+ concentration ([Ca2+]i) and growth hormone release from purified rat somatotrophs. I. GH-releasing factor-induced Ca2+ influx raises [Ca2+]i. Endocrinology 128:570-582.
229. Lutz MP, Pinon DI, Gates LK, Shenolikar S, and Miller LJ (1993) Control of cholecystokinin receptor dephosphorylation in pancreatic acinar cells. J Biol Chem 268:12136-12142.
230. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, and Pederson RA (2001) Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50:1004-1011.
231. MacLusky N, Cook S, Scrocchi L, Shin J, Kim J, Vaccarino F, Asa SL, and Drucker DJ (2000) Neuroendocrine function in mice with complete disruption of GLP-1 receptor signaling. Endocrinology 141:752-762.
232. MacNeil DJ, Occi JL, Hey PJ, Strader CD, and Graziano MP (1994) Cloning and expression of a human glucagon receptor. Biochem Biophys Res Commun 198:328-334.
233. Madsen P, Knudsen LB, Wiberg FC, and Carr RD (1998) Discovery and structureactivity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem 41:5150-5157.
234. Mallat A, Pavoine C, Dufour M, Lotersztajn S, Bataille D, and Pecker F (1987) A glucagon fragment is responsible for the inhibition of the liver Ca pump by glucagon. Nature (Lond) 325:620-622.
235. Margioris AN, Brockmann G, Bohler HC Jr, Grino M, Vamvakopoulos N, and Chrousos GP (1990) Expression and localization of growth hormone-releasing hormone messenger ribonucleic acid in rat placenta: in vitro secretion and regulation of its peptide product. Endocrinology 126:151-158.
236. Mark HF and Chow BK (1995) Localization of the gene encoding the secretin receptor, SCTR, on human chromosome 2q14.1 by fluorescence in situ hybridization and chromosome morphometry. Genomics 29:817-818.
237. Matsubara S, Sato M, Mizobuchi M, Niimi M, and Takahara J (1995) Differential gene expression of growth hormone (GH)-releasing hormone (GRH) and GRH receptor in various rat tissues. Endocrinology 136:4147-4150.
238. Mayo KE (1992) Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol 6:1734-1744.
239. Mayo KE, Cerelli GM, Rosenfeld MG, and Evans RM (1985) Characterization of cDNA and genomic clones encoding the precursor to rat hypothalamic growth hormone-releasing factor. Nature (Lond) 314:464-467.
240. Mayo KE, Godfrey PA, Suhr ST, Kulik DJ, and Rahal JO (1995) Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res 50:35-73.
241. Mayo KE, Hammer RE, Swanson LW, Brinster RL, Rosenfeld MG, and Evans RM (1988) Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Mol Endocrinol 2:606-612.
242. Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, and Cunha SR (2000) Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res 55:237-266; discussion 55:266-267.
243. Mayo KE, Miller TL, DeAlmeida V, Zheng J, and Godfrey PA (1996) The growth-hormone-releasing hormone receptor: signal transduction, gene expression and physiological function in growth regulation. Ann NY Acad Sci 805:184-203.
244. Mayo KE, Vale W, Rivier J, Rosenfeld MG, and Evans RM (1983) Expression-cloning and sequence of a cDNA encoding human growth hormone-releasing factor. Nature (Lond) 306:86-88.
245. Mazzocchi G, Rebuffat P, Meneghelli V, Malendowicz LK, Tortorella C, Gottardo G and Nussdorfer, GG (1999) Gastric inhibitory polypeptide stimulates glucocorticoid secretion in rats, acting through specific receptors coupled with the adenylate cyclase-dependent signaling pathway. Peptides 20:589-594.
246. McIntosh CH, Bremsak I, Lynn FC, Gill R, Hinke SA, Gelling R, Nian C, McKnight G, Jaspers S and Pederson, RA (1999) Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin. Endocrinology 140:398-404.
247. Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, and Nauck MA (2001) Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50:2497-2504.
248. Mentlein R, Gallwitz B, and Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835.
249. Menzel S, Stoffel M, Espinosa R 3rd, Fernald AA, Le Beau MM, and Bell GI (1994) Localization of the glucagon receptor gene to human chromosome band 17q25. Genomics 20:327-328.
250. Merchenthaler I, Lane M, and Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261-280.
251. Merchenthaler I, Vigh S, Schally AV, and Petrusz P (1984) Immunocytochemical localization of growth hormone-releasing factor in the rat hypothalamus. Endocrinology 114:1082-1085.
252. Merimee TJ (1983) Glucagon and growth hormone, in Glucagon II (Lefebvre PJ ed) pp 545-551, Springer-Verlag, Berlin.
253. Miki N, Ono M, Murata Y, Ohsaki E, Tamitsu K, Ri T, Demura H, and Yamada M (1995) Thyroid hormone regulation of gene expression of the pituitary growth hormone-releasing factor receptor. Biochem Biophys Res Commun 217:1087-1093.
254. Miki N, Ono M, Murata Y, Ohsaki E, Tamitsu K, Yamada M, and Demura H (1996) Regulation of pituitary growth hormone-releasing factor (GRF) receptor gene expression by GRF. Biochem Biophys Res Commun 224:586-590.
255. Miller TL, Godfrey PA, Dealmeida VI, and Mayo KE (1999) The rat growth hormone-releasing hormone receptor gene: structure, regulation and generation of receptor isoforms with different signaling properties. Endocrinology 140:4152-4165.
256. Miller TL and Mayo KE (1997) Glucocorticoids regulate pituitary growth hormone-releasing hormone receptor messenger ribonucleic acid expression. Endocrinology 138:2458-2465.
257. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, et al. (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738-742.
258. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, et al. (1999) Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96:14843-14847.
259. Moens K, Berger V, Ahn JM, Van Schravendijk C, Hruby VJ, Pipeleers D, and Schuit F (2002) Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells. Diabetes 51:669-675.
260. Moens K, Flamez D, Van Schravendijk C, Ling Z, Pipeleers D, and Schuit F (1998) Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors. Diabetes 47:66-72.
261. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B and Schuit, F (1996) Expression and functional activity of glucagon, glucagon-like peptide 1 and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45:257-261.
262. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, and Habener JF (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880-11889.
263. Montero M, Yon L, Kikuyama S, Dufour S, and Vaudry H (2000) Molecular evolution of the growth hormone-releasing hormone/pituitary adenylate cyclase-activating polypeptide gene family. Functional implication in the regulation of growth hormone secretion. J Mol Endocrinol 25:157-168.
264. Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, and Adams LG (1997) Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol 172:275-283.
265. Morel G, Gallego R, Boulanger L, Pintos E, Garcia-Caballero T, and Gaudreau P (1999) Restricted presence of the growth hormone-releasing hormone receptor to somatotropes in rat and human pituitaries. Neuroendocrinology 70:128-136.
266. Morris BJ and Chambers SM (1996) Hypothesis: glucagon receptor glycine to serine missense mutation contributes to one in 20 cases of essential hypertension. Clin Exp Pharmacol Physiol 23:1035-1037.
267. Motomura T, Hashimoto K, Koga M, Arita N, Hayakawa T, Kishimoto T, and Kasayama S (1998) Inhibition of signal transduction by a splice variant of the growth hormone-releasing hormone receptor expressed in human pituitary adenomas. Metab Clin Exp 47:804-808.
268. Muhlhauser I, Berger M, Sonnenberg G, Koch J, Jorgens V, Schernthaner G, Scholz V, and Padagogin D (1985) Incidence and management of severe hypoglycemia in 434 adults with insulin-dependent diabetes melhtus. Diabetes Care 8:268-273.
269. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, et al. (1999) Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 96:1569-1573.
270. Mutt V (1980) Secretin: isolation, structure and functions, in Gastrointestinal Hormones (Glass GBJ ed) pp 85-126, Raven Press, New York.
271. Mutt V, Magnusson S, Jorpes JE, and Dahl E (1966) Structure of porcine secretin I. Biochem J 4:2358.
272. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, and Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Investig 91:301-307.
273. Netchine I, Talon P, Dastot F, Vitaux F, Goossens M, and Amselem S (1998) Extensive phenotypic analysis of a family with growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. J Clin Endocrinol Metab 83:432-436.
274. Ngan ES, Chow LS, Tse DL, Du X, Wei Y, Mojsov S, and Chow BK (1999) Functional studies of a glucagon receptor isolated from frog Rana tigrina rugulosa: implications on the molecular evolution of glucagon receptors in vertebrates. FEBS Lett 457:499-504.
275. Nillni EA, Steinmetz R, and Pescovitz OH (1999) Posttranslational processing of progrowth hormone-releasing hormone. Endocrinology 140:5817-5827.
276. Nogami H, Hiraoka Y, Matsubara M, Nonobe E, Harigaya T, Katayama M, Hemmi N, Kobayashi S, Mogi K, Aiso S, et al. (2002) A composite hormone response element regulates transcription of the rat GHRH receptor gene. Endocrinology 143:1318-1326.
277. O'Harte FP, Mooney MH, and Flatt PR (1999) NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes 48:758-765.
278. O'Harte FP, Mooney MH, Kelly CM, and Flatt PR (2000) Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J Endocrinol 165:639-648.
279. Ohlsson L and Lindstrom P (1990) The correlation between calcium outflow and growth hormone release in perifused rat somatotrophs. Endocrinology 126:488-497.
280. Ono M, Miki N, Murata Y, Osaki E, Tamitsu K, Ri T, Yamada M, and Demura H (1995) Sexually dimorphic expression of pituitary growth hormone-releasing factor receptor in the rat. Biochem Biophys Res Commun 216:1060-1066.
281. Orskov C, Holst JJ, Knuhtsen S, Baldissera FGA, Poulsen SS, and Nielsen OV (1986) Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119:1467-1475.
282. Orskov C, Wettergren A, and Holst JJ (1993) Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661.
283. Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, Sunaga Y, Yano H, Matsuura Y, Iwanaga T, et al. (2000) cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2:805-811.
284. Ozcelebi F, Holtmann MH, Rentsch RU, Rao R, and Miller LJ (1995) Agonist-stimulated phosphorylation of the carboxyl-terminal tail of the secretin receptor. Mol Pharmacol 48:818-824.
285. Park CG, Ganguli SC, Pinon DI, Hadac EM, and Miller LJ (2000) Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation. J Pharmacol Exp Ther 295:682-688.
286. Parker JC, Andrews KM, Allen MR, Stock JL, and McNeish JD (2002) Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290:839-843.
287. Parker JC, Andrews KM, Rescek DM, Massefski W Jr, Andrews GC, Contillo LG, Stevenson RW, Singleton DH, and Suleske RT (1998) Structure-function analysis of a series of glucagon-like peptide-1 analogs. J Pept Res 52:398-409.
288. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, and Demuth HU (1996) Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J Biol Chem 271:23222-23229.
289. Peng XD, Park S, Gadelha MR, Coschigano KT, Kopchick JJ, Frohman LA and Kineman, RD (2001) The growth hormone (GH)-axis of GH receptor/binding protein gene-disrupted and metallothionein-human GH-releasing hormone transgenic mice: hypothalamic neuropeptide and pituitary receptor expression in the absence and presence of GH feedback. Endocrinology 142:1117-1123.
290. Perry T, Haughey NJ, Mattson MP, Egan JM, and Greig NH (2002a) Protection and reversal of excitotoxic neuronal damage by glucagon-like Peptide-1 and exendin-4. J Pharmacol Exp Ther 302:881-888.
291. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, and Greig NH (2002b) A novel neurotrophic property of glucagon-like Peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300:958-966.
292. Petersen KF and Sullivan JT (2001) Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018-2024.
293. Petersenn S, Rasch AC, Heyens M, and Schulte HM (1998) Structure and regulation of the human growth hormone-releasing hormone receptor gene. Mol Endocrinol 12:233-247.
294. Pombo CM, Zalvide J, Gaylinn BD, and Dieguez C (2000) Growth hormone-releasing hormone stimulates mitogen-activated protein kinase. Endocrinology 141:2113-2119.
295. Portois L, Maget B, Tastenoy M, Perret J, and Svoboda M (1999) Identification of a glucose response element in the promoter ofthe rat glucagon receptor gene. J Biol Chem 274:8181-8190.
296. Prasad R, Alavi K, and Schwartz MZ (2000) Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg 35:357-359.
297. Prasad R, Alavi K, and Schwartz MZ (2001) GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion. J Pediatr Surg 36:570-572.
298. Ramirez JL, Castano JP, Torronteras R, Martinez-Fuentes AJ, Frawley LS, Garcia-Navarro S, and Gracia-Navarro F (1999) Growth hormone (GH)-releasing factor differentially activates cyclic adenosine 3′, 5′-monophosphate- and inositol phosphate-dependent pathways to stimulate GH release in two porcine somatotrope subpopulations. Endocrinology 140:1752-1759.
299. Rask E, Olsson T, Soderberg S, Johnson O, Seckl J, Holst JJ, and Ahren B (2001) Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24:1640-1645.
300. Rekasi Z, Czompoly T, Schally AV, and Halmos G (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 97:10561-10566.
301. Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, Lebrethon MC, Budi I, Balliere AM, and Mahoudeau J (1992) Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide [see comments]. N Engl J Med 327:981-986.
302. Richter G, Goke R, Goke B, and Arnold R (1990) Characterization of receptors for glucagon-like peptide-1(7-36)amide on rat lung membranes. FEBS Lett 267:78-80.
303. Richter G, Goke R, Goke B, Schmidt H, and Arnold R (1991) Characterization of glucagon-like peptide-I(7-36)amide receptors of rat lung membranes by covalent cross-linking. FEBS Lett 280:247-250.
304. Ritzel U, Leonhardt U, Ottleben M, Ruhmann A, Eckart K, Spiess J, and Ramadori G (1998) A synthetic glucagon-like peptide-1 analog with improved plasma stability. J Endocrinol 159:93-102.
305. Rivier J, Spiess J, Thorner M, and Vale W (1982) Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature (Lond) 300:276-278.
306. Robberecht P, Coy DH, Waelbroeck M, Heiman ML, de Neef P, Camus JC, and Christophe J (1985) Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes. Endocrinology 117:1759-1764.
307. Rodbell M, Birnbaumer L, Pohl SL, and Krans HM (1971a) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanylnucleotides in glucagon action. J Biol Chem 246:1877-1882.
308. Rodbell M, Krans HM, Pohl SL, and Birnbaumer L (1971b) The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. 3. Binding of glucagon: method of assay and specificity. J Biol Chem 246:1861-1871.
309. Rodier G, Magous R, Mochizuki T, Le Nguyen D, Martinez J, Bali JP, Bataille D, Jarrousse C and Genevieve, R (1999) Glicentin and oxyntomodulin modulate both the phosphoinositide and cyclic adenosine monophosphate signaling pathways in gastric myocytes. Endocrinology 140:22-28.
310. Salvatori R, Fan X, Mullis PE, Haile A, and Levine MA (2002) Decreased expression of the GHRH receptor gene due to a mutation in a Pit-1 binding site. Mol Endocrinol 16:450-458.
311. Salvatori R, Fan X, Phillips JA 3rd, Espigares-Martin R, Martin De Lara I, Freeman KL, Plotnick L, Al-Ashwal A, and Levine, MA (2001a) Three new mutations in the gene for the growth hormone (gh)-releasing hormone receptor in familial isolated gh deficiency type ib. J Clin Endocrinol Metab 86:273-279.
312. Salvatori R, Hayashida CY, Aguiar-Oliveira MH, Phillips JA 3rd, Souza AH, Gondo RG, Toledo SP, Conceicao MM, Prince M, Maheshwari HG, et al. (1999) Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor gene. J Clin Endocrinol Metab 84:917-923.
313. Salvatori R, Thakker RV, Lopes MB, Fan X, Eswara JR, Ellison D, Lees P, Harding B, Yang I, and Levine MA (2001b) Absence of mutations in the growth hormone (GH)-releasing hormone receptor gene in GH-secreting pituitary adenomas. Clin Endocrinol 54:301-307.
314. Samols E, Marri G, and Marks V (1966) Interrelationship of glucagon, insulin and glucose: the insulinogenic effect of glucagon. Diabetes 15:855-865.
315. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, et al. (1999) Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48:1045-1053.
316. Sato M and Takahara J (1997) Gene regulation of growth hormone-releasing hormone and its receptor. Endocr J 44:765-774.
317. Sawchenko PE, Swanson LW, Rivier J, and Vale WW (1985) The distribution of growth-hormone-releasing factor (GRF) immunoreactivity in the central nervous system of the rat: an immunohistochemical study using antisera directed against rat hypothalamic GRF. J Comp Neurol 237:100-115.
318. Schally AV and Varga JL (1999) Antagonistic analogs of growth hormone-releasing hormone:new potential antitumor agents. Trends Endocrinol Metab 10:383-391.
319. Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Goke B, and Katschinski M (1997) Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility and pancreatic function in men. Proc Assoc Am Physicians 109:84-97.
320. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, and Katschinski M (1998) Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Investig 101:1421-1430.
321. Schmidtler J, Dehne K, Allescher H-D, Schusdziarra V, Classen M, Holst JJ, Polack A, and Schepp W (1994) Rat parietal cell receptors for GLP-1-(7-36) amide: Northern blot, cross-linking and radioligand binding. Am J Physiol 267:G423-G432.
322. Scott RB, Kirk D, MacNaughton WK, and Meddings JB (1998) GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 275:G911-G921.
323. Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, and Drucker DJ (1996) Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat Med 2:1254-1258.
324. Scrocchi LA, Hill ME, Saleh J, Perkins B, and Drucker DJ (2000) Elimination of GLP-1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes 49:1552-1560.
325. Seeley RJ, Woods SC, and D'Alessio D (2000) Targeted gene disruption in endocrine research: The case of GLP-1 and neuroendocrine function. Endocrinology 141:473-475.
326. Seifert H, Perrin M, Rivier J, and Vale W (1985) Binding sites for growth hormone releasing factor on rat anterior pituitary cells. Nature (Lond) 313:487-489.
327. Shetzline MA, Premont RT, Walker JK, Vigna SR, and Caron MG (1998) A role for receptor kinases in the regulation of class II G protein-coupled receptors. Phosphorylation and desensitization of the secretin receptor. J Biol Chem 273:6756-6762.
328. Shimizu I, Hirota M, Ohboshi C, and Shima K (1987) Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121:1076-1082.
329. Shiota D, Kasamatsu T, Dib SA, Chacra AR, and Moises RS (2002) Role of the Gly40Ser mutation in the glucagon receptor gene in Brazilian patients with type 2 diabetes mellitus. Pancreas 24:386-390.
330. Shughrue PJ, Lane MV, and Merchenthaler I (1996) Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137:5159-5162.
331. Siegel EG, Gallwitz B, Scharf G, Mentlein R, Morys-Wortmann C, Folsch UR, Schrezenmeir J, Drescher K, and Schmidt WE (1999) Biological activity of GLP1-analogues with N-terminal modifications. Regul Pept 79:93-102.
332. Sivarajah P, Wheeler MB, and Irwin DM (2001) Evolution of receptors for proglucagon-derived peptides: isolation of frog glucagon receptors. Comp Biochem Physiol Part B Comp Biochem Mol Biol 128:517-527.
333. Spiess J, Rivier J, and Vale W (1983) Characterization of rat hypothalamic growth hormone-releasing factor. Nature (Lond) 303:532-535.
334. Stalmans W (1983) Glucagon and liver glycogen metabolism, in Glucagon I (Lefebvre PJ ed) pp 291-314, Springer-Verlag, Berlin.
335. Stefaneanu L, Kovacs K, Horvath E, Asa SL, Losinski NE, Billestrup N, Price J, and Vale W (1989) Adenohypophysial changes in mice transgenic for human growth hormone-releasing factor: a histological, immunocytochemical and electron microscopic investigation. Endocrinology 125:2710-2718.
336. Steinberg DM, Shafrir E, and Vaughan M (1959) Direct effect of glucagon on release of unesterified fatty acids (UFA) from adipose tissue. Clin Res 7:250.
337. Stephanou A, Knight RA, and Lightman SL (1991) Production of a growth hormone-releasing hormone-like peptide and its mRNA by human lymphocytes. Neuroendocrinology 53:628-633.
338. Stoffel M, Espinosa R III, Le Beau MM, and Bell GI (1993) Human glucagon-like peptide-1 receptor gene: localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6. Diabetes 42:1215-1218.
339. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Egan JM, Bonner-Weir S, and Habener JF (2000) Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas. Diabetes 49:741-748.
340. Suhr ST, Rahal JO, and Mayo KE (1989) Mouse growth-hormone-releasing hormone: precursor structure and expression in brain and placenta. Mol Endocrinol 3:1693-1700.
341. Sutherland EW (1950) The effect of the hyperglycemic factor of the pancreas and of epinephrine on glycogenolysis. Recent Prog Horm Res 5:441-459.
342. Svoboda M, Ciccarelli E, Tastenoy M, Robberecht P, and Christophe J (1993) A cDNA construct allowing the expression of rat hepatic glucagon receptors. Biochem Biophys Res Commun 192:135-142.
343. Svoboda M, Tastenoy M, De Neef P, Delporte C, Waelbroeck M, and Robberecht P (1998) Molecular cloning and in vitro properties of the recombinant rabbit secretin receptor. Peptides 19:1055-1062.
344. Svoboda M, Tastenoy M, Vertongen P, and Robberecht P (1994) Relative quantitative analysis of glucagon receptor mRNA in rat tissues. Mol Cell Endocrinol 105:131-137.
345. Takahashi T, Okimura Y, Yoshimura K, Shigeyoshi Y, Kaji H, Abe H, and Chihara K (1995) Regional distribution of growth hormone-releasing hormone (GHRH) receptor mRNA in the rat brain. Endocrinology 136:4721-4724.
346. Tang J, Lagace G, Castagne J, and Collu R (1995) Identification of human growth hormone-releasing hormone receptor splicing variants. J Clin Endocrinol Metab 80:2381-2387.
347. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, and Vrang N (2000) The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter in-volved in the regulation of food intake. Nat Med 6:802-807.
348. Thorens B (1992) Expression cloning of the pancreatic β cell receptor for the glucoincretin hormone glucagon-like peptide 1. Proe Natl Acad Sci USA 89:8641-8645.
349. Thorens B, Porret A, BŸhler L, Deng S-P, Morel P, and Widmann C (1993) Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42:1678-1682.
350. Thorens B and Widmann C (1996) Structure and function of the glucagon-like peptide-1 receptor, in Handbook of Experimental Pharmacology Glucagon III (Lefebvre PJ ed) pp 255-273, Springer-Verlag, Berlin.
351. Thorner MO, Perryman RL, Cronin MJ, Rogol AD, Draznin M, Johanson A, Vale W, Horvath E, and Kovacs K (1982) Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Investig 70:965-977.
352. Thulesen J, Hartmann B, Orskov C, Jeppesen PB, Holst JJ, and Poulsen SS (2000) Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i. v. injected (125)I-GLP-2. Peptides 21:1511-1517.
353. Thulesen J, Knudsen LB, Hartmann B, Hastrup S, Kissow H, Jeppesen PB, Orskov C, Holst JJ, and Poulsen SS (2002) The truncated metabolite GLP-2(3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept 103:9-15.
354. Tibaduiza EC, Chen C, and Beinborn M (2001) A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem 276:37787-37793.
355. Trimble ER, Bruzzone R, Biden TJ, Meehan CJ, Andreu D, and Merrifield RB (1987) Secretin stimulates cyclic AMP and inositol trisphosphate production in rat pancreatic acinar tissue by two fully independent mechanisms. Proc Natl Acad Sci USA 84:3146-3150.
356. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, and Horsch D (2001) Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15:1559-1570.
357. Tsai C-H, Hill M, Asa SL, Brubaker PL, and Drucker DJ (1997a) Intestinal growth-promoting properties of glucagon-like peptide 2 in mice. Am J Physiol 273:E77-E84.
358. Tsai C-H, Hill M, and Drucker DJ (1997b) Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol 272:G662-G668.
359. Tseng CC, Jarboe LA, Landau SB, Williams EK, and Wolfe MM (1993) Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat. Proc Natl Acad Sci USA 90:1992-1996.
360. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, and Wolfe MM (1996) Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Investig 98:2440-2445.
361. Tseng C-C and Lin L (1997) A point mutation in the glucose-dependent insulinotropic peptide receptor confers constitutive activity. Biochem Biophys Res Commun 232:96-100.
362. Tseng CC and Zhang XY (1998) The cysteine of the cytoplasmic tail of glucose-dependent insulinotropic peptide receptor mediates its chronic desensitization and down-regulation. Mol Cell Endocrinol 139:179-186.
363. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (Lond) 379:69-72.
364. Ulrich CD, Holtmann M, and Miller LJ (1998) Secretin and vasoactive intestinal peptide receptors: Members of a unique family of G protein-coupled receptors. Gastroenterology 114:382-397.
365. Ulrich CD 2nd, Pinon DI, Hadac EM, Holicky EL, Chang-Miller A, Gates LK, and Miller LJ (1993) Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors. Gastroenterology 105:1534-1543.
366. Unger RH and Eisentraut AM (1969) Entero-insular axis. Arch Int Med 123:261-266.
367. Unson CG, Cypess AM, Kim HN, Goldsmith PK, Carruthers CJL, Merrifield RB, and Sakmar TP (1995) Characterization of deletion and truncation mutants of the rat glucagon receptor. Seven transmembrane segments are necessary for receptor transport to the plasma membrane and glucagon binding. J Biol Chem 270:27720-27727.
368. Unson CG, Macdonald D, and Merrifield RB (1993) The role of histidine-1 in glucagon action. Arch Biochem Biophys 300:747-750.
369. Unson CG, Macdonald D, Ray K, Durrah TL, and Merrifield RB (1991) Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding. J Biol Chem 266:2763-2766.
370. Unson CG and Merrifield RB (1994) Identification of an essential serine residue in glucagon: implication for an active site triad. Proc Natl Acad Sci USA 91:454-458.
371. Unson CG, Wu CR, Jiang Y, Yoo B, Cheung C, Sakmar TP, and Merrifield RB (2002) Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling. Biochemistry 41:11795-11803.
372. Unson CG, Wu CR, Sakmar TP, and Merrifield RB (2000) Selective stabilization of the high affinity binding conformation of glucagon receptor by the long splice variant of Galpha(s). J Biol Chem 275:21631-21638.
373. Usdin TB, Mezey E, Button DC, Brownstein MJ, and Bonner TI (1993) Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133:2861-2870.
374. Uttenthal LO and Blazquez E (1990) Characterization of high affinity receptors for glucagon-like peptide-1 in rat gastric glands. FEBS Lett 262:139-141.
375. Valverde I, Merida E, Delgado E, Trapote MA, and Villanueva-Penacarillo ML (1993) Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue. Endocrinology 132:75-79.
376. Van Eyll B, Lankat-Buttgereit B, Bode HP, Goke R, and Goke B (1994) Signal transduction of the GLP-1-receptor cloned from a human insulinoma. FEBS Lett 348:7-13.
377. Varga JL, Schally AV, Csernus VJ, Zarandi M, Halmos G, Groot K, and Rekasi Z (1999) Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci USA 96:692-697.
378. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, and Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269-324.
379. Velicelebi G, Santacroce TM, and Harpold MM (1985) Specific binding of synthetic human pancreatic growth hormone releasing factor (1-40-OH) to bovine anterior pituitaries. Biochem Biophys Res Commun 126:33-39.
380. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, and Astrup A (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382-4389.
381. Vilardaga JP, De Neef P, Di Paolo E, Bollen A, Waelbroeck M, and Robberecht P (1995) Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination. Biochem Biophys Res Commun 211:885-891.
382. Vilsboll T, Krarup T, Deacon CF, Madsbad S, and Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613.
383. Wajnrajch MP, Chua SC, Green ED, and Leibel RL (1994) Human growth hormone-releasing hormone receptor (GHRHR) maps to a YAC at chromosome 7p15. Mamm Genome 5:595.
384. Wajnrajch MP, Gertner JM, Harbison MD, Chua SC Jr, and Leibel RL (1996) Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat Genet 12:88-90.
385. Wakelam MJ, Murphy GJ, Hruby VJ, and Houslay MD (1986) Activation of two signal-transduction systems in hepatocytes by glucagon. Nature (Lond) 323:68-71.
386. Wei Y and Mojsov S (1995) Tissue-specific expression of the human receptor for glucagon-like peptide 1: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358:219-224.
387. Wheeler MB, Gelling RW, Hinke SA, Tu B, Pederson RA, Lynn F, Ehses J, and McIntosh CH (1999) Characterization of the carboxyl-terminal domain of the rat glucose-dependent insulinotropic polypeptide (GIP) receptor. A role for serines 426 and 427 in regulating the rate of internalization. J Biol Chem 274:24593-24601.
388. Wheeler MB, Gelling RW, McIntosh CH, Georgiou J, Brown JC, and Pederson RA (1995) Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 136:4629-4639.
389. Widmann C, Dolci W, and Thorens B (1997) Internalization and homologous desensitization of the GLP-1 receptor depend on phosphorylation of the receptor carboxyl tail at the same three sites. Mol Endocrinol 11:1094-1102.
390. Wildhage I, Trusheim H, Goke B, and Lankat-Buttgereit B (1999) Gene expression of the human glucagon-like peptide-1 receptor is regulated by Sp1 and Sp3. Endocrinology 140:624-631.
391. Wilmen A, Van Eyll B, Goke B, and Goke R (1997) Five out ofsix tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1. Peptides 18:301-305.
392. Xiao Q, Boushey RP, Cino M, Drucker DJ, and Brubaker PL (2000a) Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol 278:R1057-R1063.
393. Xiao Q, Boushey RP, Drucker DJ, and Brubaker PL (1999) Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 117:99-105.
394. Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, and Wheeler MB (2001) Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40:2860-2869.
395. Xiao Q, Jeng W, and Wheeler MB (2000b) Characterization of glucagon-like peptide-1 receptor-binding determinants. J Mol Endocrinol 25:321-335.
396. Yada T, Itoh K, and Nakata M (1993) Glucagon-like peptide-1-(7-36)amide and a rise in cyclic adenosine 3′, 5′-monophosphate increase cytosolic free Ca2+ in rat pancreatic b-cells by enhancing Ca2+ channel activity. Endocrinology 133:1685-1692.
397. Yamada Y, Hayami T, Nakamura K, Kaisaki PJ, Someya Y, Wang CZ, Seino S, and Seino Y (1995) Human gastric inhibitory polypeptide receptor: cloning of the gene (GIPR) and cDNA. Genomics 29:773-776.
398. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, et al. (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Investig 110:43-52.
399. Yamato E, Ikegami H, Takekawa K, Fujisawa T, Nakagawa Y, Hamada Y, Ueda H, and Ogihara T (1997) Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1). Horm Metab Res 29:56-59.
400. Yasuda K, Inagaki N, Yamada Y, Kubota A, Seino S, and Seino Y (1994) Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells: its structure and functional properties. Biochem Biophys Res Commun 205:1556-1562.
401. Yip RG and Wolfe MM (2000) GIP biology and fat metabolism. Life Sci 66:91-103.
402. Yusta B, Boushey RP, and Drucker DJ (2000a) The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem 275:35345-35352.
403. Yusta B, Estall J, and Drucker DJ (2002) Glucago-like peptide-2 receptor activation engages Bad and glycogen synthase kinase 3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem 277:24896-24906.
404. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, and Drucker DJ (2000b) Enteroendocrine localization of GLP-2 receptor expression. Gastroenterology 119:744-755.
405. Yusta B, Somwar R, Wang F, Munroe D, Grinstein S, Klip A, and Drucker DJ (1999) Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J Biol Chem 274:30459-30467.
406. Zander M, Madsbad S, Madsen JL, and Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830.
407. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, and Schally AV (1994) Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 91:12298-12302.
408. Zeitler P and Siriwardana G (2000) Stimulation of mitogen-activated protein kinase pathway in rat somatotrophs by growth hormone-releasing hormone. Endocrine 12:257-264.
409. Zeitler P, Stevens P, and Siriwardana G (1998) Functional GHRH receptor carboxyl terminal isoforms in normal and dwarf (dw) rats. J Mol Endocrinol 21:363-371.
410. Zhang BB and Moller DE (2000) New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol 4:461-467.
411. Zhong Q, Bollag RJ, Dransfield DT, Gasalla-Herraiz J, Ding KH, Min L, and Isales CM (2000) Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells. Peptides 21:1427-1432.
412. Zhu X, Zhou A, Dey A, Norrbom C, Carroll R, Zhang C, Laurent V, Lindberg I, Ugleholdt R, Holst JJ, et al. (2002) Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci USA 99:10293-10298.